Abstract

IN VITRO AND IN VIVO EVALUATION ACTIVITIES OF EACH MESENCHYMAL STEM CELLS, DOXORUBICIN AND LPS OR COMBINED ON BREAST CARCINOMA

Mohamed T Abd El Aziz, Dina Sabry, Mohamed A S Al-Ghussein*, Abeer M A Soliman, Ayman A Hassan

ABSTRACT

Aim: We aimed to explore in vitro and in vivo activities by one or combined therapy of hMSCs, doxorubicin or LPS against breast cancer MCF7. Methods: MCF7, hMSCs and coculture were cultivated, harvested and exposed to either or doxorubicin or LPS in groups then examined by Flow Cytometer for in vitro examinations. Cell proliferation was investigated by MTT assay and both PJNK and IL-6 levels by ELISA. In vitro genes’ expression was examined by qRTPCR for TLR4, VEGF, NF-ƘB, IL-8 and IL-1. In vivo cancer induction was performed for 70 albino mice that exposed to treatments before and followed by pathological examination and measuring the same genes’ expression. Results: In vitro results showed significant reduction in MCF7 proliferation, PJNK, IL-6 and genes’; TLR4, VEGF, NF-ƘB, IL-8 and IL-1; expression for groups’ hMSCs and/or doxorubicin but LPS was an exception in PJNK and IL-6 levels elevation. In vivo results supported the previous by reduction in cancer cells number when mixed with hMSCs. Similar genes expression reductions were noticed for hMSCs and/or doxorubicin but LPS also appeared as exception in genes’ expression elevation due to its antigenic properties. Conclusions: Each of hMSCs, doxorubicin or LPS was effective alone but appeared more effective when combined together. hMSCs combined with doxorubicin therapy achieves the highest benefits. Even if LPS showed some antigenic properties but it stills reduced MCF7 proliferation.

Keywords: MCF7, hMSCs, doxorubicin, LPS.